量研学術機関リポジトリ「QST-Repository」は、国立研究開発法人 量子科学技術研究開発機構に所属する職員等が生み出した学術成果（学会誌発表論文、学会発表、研究開発報告書、特許等）を集積しインターネット上で広く公開するサービスです。 Welcome to QST-Repository where we accumulates and discloses the academic research results(Journal Publications, Conference presentation, Research and Development Report, Patent, etc.) of the members of National Institutes for Quantum and Radiological Science and Technology.
Thank you very much for using our website. On the 11th of March 2019, this site was moved from our own network server to the JAIRO Cloud network server. If you previously bookmarked this site, that bookmark will no longer work. We would be grateful if you could bookmark the website again. Thank you very much for your understanding and cooperation.
Background: We reported that the 4-fraction/1-week carbon ion radiotherapy, that had been conducted from April 2001 to February 2003 within a phase II clinical study, appeared to be safe and to have a promising potential as a new, radical, and minimally invasive therapeutic option for hepatocellular carcinoma (HCC) at the last ASCO annual meeting. The next clinical trial of 2-fraction/2-day carbon ion radiotherapy is going on within a phase I/II study from April 2003. Patients and Methods: Twenty-five patients with histologically proven HCC were treated with 2-fraction/2-day carbon ion radiotherapy of 32.0GyE in 6, 33.6GyE in 7, 35.2GyE in 6, and 37.0GyE in 6 in a step-wise dose-escalation study from April 2003 to August 2004. Common Toxicity Criteria, RTOG/EORTC criteria were used for evaluation of toxicity. Serial changes in Child-Pugh score were investigated after the start of therapy to evaluate its invasiveness to the liver. Anti-tumor effect was evaluated by the tumor response and directly- calculated local control rate. Results: During a median follow-up of 12.1 (3.9-19.5) months, no severe adverse effects and no treatment-related deaths occurred. In the early phase, no change in the Child-Pugh score was observed in 79% (19/24), only a 1-point increase in 17% (4/24), and 2-point increase in 4% (1/24) of the patients. In the late phase, similar observations were made in 75% (12/16), 6% (1/16), and 19% (3/16), respectively. The overall tumor response rate was 96% (24/25) at 6 months after the therapy. Local control rates were 96% (24/25) and 93% (13/14) at 6 and 12 months, respectively. Overall survival rates were 100% at 6 and 12 months, respectively. There were preliminarily no differences between the results in the current study and those in the 4-fraction carbon ion radiotherapy. Conclusion: Two-fraction carbon ion radiotherapy for HCC appears preliminarily to be safe and effective. However, further observation is needed to confirm its clinical usefulness.
会議概要（会議名, 開催地, 会期, 主催者等）
American Society of Clinical Oncology Annual Meeting 2005
Two-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma: Preliminary Results of a Phase I/II Clinical Trial
